Drugs / Cistanche Total Glycosides
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00753571 Comparator | Jan → Dec 2008 | amyotrophic lateral sclerosis | Peking University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cistanche Total Glycosides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00753571 ↗ |
| Known as | CTG | “This study will examine the effectiveness of Cistanche Total Glycosides(CTG) in treating patients with amyotrophic lateral sclerosis (ALS)” NCT00753571 ↗ |
| Route | Oral | “Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd” NCT00753571 ↗ |